Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Dermatologic 4Thoracic 2Gastrointestinal 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Pancreatic Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × tovorafenib × Thoracic × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07121829 2025-08-14

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 1 Terminated
44 enrolled
CNSDermatologicGastrointestinalThoracic

Astrocytoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡